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Abstract. Sixteen girls with Turner syndrome (TS) were 
treated for 4 years with biosynthetic growth hormone 
(GH).  The dosage was 4 IU/m 2 body surface s.c. per day 
over the first 3 years. In the 4th year the dosage was in- 
creased to 6 IU /m 2 per day in the 6 girls with a poor 
height increment and in i girl oxandrolone was added. 
Ethinyl oestradiol was added after the age of 13. Mean 
(SD) growth velocities were 3.4 (0.9), 7.2 (1.7), 5.3 (1.3), 
4.3 (2.0) and 3.6 (1.5) cm/year before and in the 1st, 
2nd, 3rd and 4th year of treatment. Skeletal maturat ion 
advanced faster than usual in Turner patients especially 
in the younger children. A l though the mean height pre- 
diction increased by 5.6 cm and 11 of the 16 girls have 
now exceeded their predicted height, the height of the 4 
girls who stopped GH treatment exceeded the predicted 
adult height by only 0 to 3.4 cm. 
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Introduction 
Turner syndrome (TS) is a genetic disorder which is asso- 
ciated with short stature [5, 7, 13, 14]. The reason for this 
growth failure is unknown and cannot be explained by 
growth hormone (GH) deficiency [3, 6]. In spite of this, 
biosynthetic GH has been advocated for patients with 
TS. Preliminary results of GH treatment in girls with TS 
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Abbreviations: GH = growth hormone; GP = Greulich and 
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have revealed an acceleration of statural growth, but so 
far few data are available about epiphyseal maturat ion 
during GH treatment. 
In two earlier papers [9, 10] we have reported the re- 
sponse to biosynthetic methionyl human GH adminis- 
tered subcutaneously once daily at a dosage of 4 IU/m 2 
body surface for a period of I and 2 years. We now pre- 
sent the 4-year results. 
Patients and methods 
Patients and therapy 
Sixteen girls with TS entered the study. During the first 2 years the 
children received methionyl GH (Somatonorm, Kabi, Stockholm, 
Sweden) and in the 3rd and 4th year they received recombinant 
authentic GH (Genotropin, Kabi, Stockholm, Sweden) in a daily 
dosage of 4 IU/m 2 body surface subcutaneously (equivalent to 0.9 
(0.26) IU/kg body weight per week). If the height increment over 
the preceding 6 months was below lcm, the GH dosage was in- 
creased to 6IU/m 2 in six patients after 36 to 45 months of treat- 
ment. GH treatment was discontinued if height increment was less 
than 0.5 cm over the previous 6months. Low dose ethinyl oestradiol 
(0.1 gg/kg od, orally) was added in patients over the age of 13. In 
this report he results for the 13 patients who completed the 4-year 
period are given. The remaining three cases and also the two cases 
who discontinued treatment after 4-years of GH treatment are de- 
scribed individually. 
Growth analysis 
Height was expressed inSDS using the Dutch cross-sectional refer- 
ences [8] (SDS(XX)) and the references for Turner girls compiled 
by Lyon et al. (SDS(XO)) [5]. The growth velocity was expressed 
as cm/year and for comparison the velocity curves of girls with TS 
prepared by Ranke et al. were used [7]. 
The skeletal maturation (Tanner and Whitehouse 20-bones 
(TW-20), Tanner and Whitehouse-RUS (TW-RUS) [15] and Greu- 
lich and Pyle (GP) [1] was assessed by an experienced investigator. 
The advancement in bone age (TW-RUS) was compared with 
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Turner references [7]. For the present report we also analysed the 
roentgenographs serially with the GP atlas without using the scores 
of the carpal bones. This method was chosen because it has been 
shown that the maturation of carpal bones is not an important de- 
terminant in adult height prediction [16]. 
The relationship of the height increment to skeletal maturation 
was assessed by computing the height SDS for bone age: the 
"index of potential height (IPH)" described by Lenko [4] and Joss 
[2] by using mean (SD) height values for bone age (TW-RUS) in 
patients with Turner syndrome. 
The prediction of adult height was calculated on the basis of the 
tables of Bayley-Pinneau and on the basis of extrapolating initial 
height SDS (projected adult height) [11]. 
For more details about patients and methods the reader is re- 
ferred to the previous reports [9, 10]. 
Statistical analysis 
Results are expressed as mean (SD) except if indicated otherwise. 
The paired Student -test and the Wilcoxon matched paired signed 
rank test were used for the analysis of within-group changes. The 
correlations between various parameters were calculated by the 
Spearman correlation test. 
Results 
Growth 
The results of the 13 patients who completed the 4-year 
treatment period are given in Table 1. Height expressed 
as SDS (XO) increased significantly during treatment. 
We observed a significant negative correlation (P = 
0.001) between the increment in height (cm) after 4 
years of treatment and age. The increment in height ex- 
pressed as SDS for Turner references was not correlated 
with age. 
Growth velocities during the 1st, 2nd and 3rd year 
were significantly higher than before treatment. The 
growth velocity in the 4th year was not significantly dif- 
ferent from that prior to treatment. In three of the six 
patients the increase in GH dosage led to a growth veloc- 
ity increment of 0.9, 1.8 and 1.8cm. However, this in- 
crease was of short duration (approximately 6 months). 
In the other three patients the growth velocity further 
decreased. 
Four patients discontinued treatment and 1 patient 
changed treatment because of a poor growth velocity of 
0.6 to 1.3 cm/year. The results are summarized in Table 
2 and the individual growth curves are given in Fig. 1. 
Skeletal maturation and predicted adult height 
Skeletal maturation (TW-RUS) during the treatment pe- 
riod was 4.2 (1.3) years, significantly (P = 0.001) higher 
than expected in untreated patients with TS during the 
same period (3.1 (0.7)) [7]. In Fig. 2a and b skeletal mat- 
uration in relation to age is visualized, before and after 3 
years of treatment. Three years was taken because dur- 
ing the 4th year several children discontinued treatment. 
The increment in the bone age (TW-RUS) was signifi- 
cantly negatively correlated with chronological ge (P = 
0.01). To exclude the effect of oestrogens on skeletal 
maturation we evaluated the data of the 6 patients who 
received only GH during 3 years. The bone age (TW- 
RUS) in these six patients increased by 3.8 (0.7) years, 
significantly more (P < 0.05) than the expected change 
(2.8 (0.2)) over this period. 
The mean (SD) index of potential height for Turner 
girls increased significantly during treatment; his corre- 
sponds to an improvement of approximately 5 cm in final 
height. The mean (SD) height prediction (GP) increased 
by 5.6 (5.1) cm. Besides the four girls who stopped treat- 
ment, seven others exceeded their predicted adult height 
Table 1. Selected growth variables over 4 years. Mean (SD) 
0 1 2 3 4 
Height SDS (XX) -3.8 (0.9) -3.4 (1.1)** -3.3 (1.2)** -3.3 (1.3) -3 .1  (1.1)* 
Height SDS (XO) 0.1 (0.8) 0.7 (0.8)*** 1.1 (0.9)*** 1.4 (1.0)*** 1.5 (1.1)*** 
HV (cm/year) 3.4 (1.0) 7.6 (1.6)*** 5.6 (1.1)*** 4.8 (1.9)* 3.6 (1.5) 
BA (TW20) 9.9 (1.3) 11.0 (1.3) 11.8 (1.0) 12.6 (0.9) 13.7 (0.8) 
BA (TW-RUS) 9.9 (1.6) 11.4 (1.5) 12.3 (1.0) 13.3 (1.0) 14.1 (0.9) 
BA (GP) 9.6 (1.4) 10.8 (1.1) 11.9 (1.0) 12.8 (0.8) 13.5 (1.0) 
Height (SDS-BA) -0.1 (0.6) 0.3 (0.7)* 0.6 (0.7)*** 0.8 (1.0)** 0.8 (1.0)** 
PAH 145.0 (5.1) 147.5 (5.4)* 147.5 (5.1) 149.3 (5.8)** 150.6 (5.8)** 
Significantly different from the value before therapy 
*P<0.05; **P<0.01; ***P <0.001 
Table 2. Selected ata of the 4 patients who 
disontinued treatment 
Case Before treatment Stop treatment 
Age BA Height PAH Age BA 
(sDs) 
Height Height 
(cm) (sDs) 
1 13.1 11.5 0.2 142.1 16.6 15.0 142.5 0.4 
2 14.1 11.8 0.1 144.3 17.8 13.8 147.6 0.8 
3 9.6 8.3 1.2 152.4 13.6 13.6 152.6 2.3 
4 12.4 10.8 0.7 145.4 16.4 16.4 145.4 0.9 
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Fig. 1. Individual growth curves of 
the patients who discontinued 
treatment. (a-d representing cases 
1-4) the interrupted line represents 
the adult height prediction based 
on the initial height SDS position 
and the continuous line represents 
the adult height prediction based 
on GP 
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Fig. 2. Bone ages (TW-RUS) of all 
patients before (a) and after (b) 3 
years of GH treatment plotted 
against the mean bone age for 
Turner girls in relation to age 
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Fig. 3. The difference between 
actual height after 4 years of 
treatment and initially predicted 
adult height (a) and projected 
adult height (b) in relation to age. 
The open circles visualize the 
patients who discontinued GH 
treatment and the closed circles 
the patients who are still on 
treatment 
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by 0.03 to 8.8 cm. Eleven girls exceeded their projected 
adult height by 1.0 to 9.2cm. The difference between 
statural height after 4 years of treatment and predicted 
or projected adult height in relation to age is shown in 
Figs. 3a and b. 
In the four patients who discontinued treatment bone 
age (GP) at discontinuation of treatment varied between 
13.9 and 15 years and height was 0 to 3.4 cm above their 
initially predicted adult height and -2 .2  to +4 cm above 
their initially projected height. Growth velocity was poor 
(1.1cm/year) in one patient during GH treatment de- 
spite a bone age of only 12.3 years and it was decided to 
add oxandrolone to the medication. Hereafter the growth 
velocity increased to 5.1 cm/year. 
Intefcurrent events 
No relevant events were reported. 
Discussion 
Our results confirm that treatment with GH promotes 
growth in children with TS. GH treatment resulted in a 
significant increase in height velocity and in height Z- 
score (SDS) using Turner references. The increment in 
height SDS in our study after 3 years of treatment (1.4SD) 
is higher than found in the American study using GH 
alone in 3 injections/wk (0.9 SD) but less than in the chil- 
dren on GH and oxandrolone (2.1SD) [11, 12]. In the 
4th year there was little change in height SDS. There 
was a progressively diminishing effect of GH therapy on 
growth velocity. 
To reach a higher final height, the increase in height 
must outweigh the increase in epiphyseal maturation. 
During treatment, skeletal maturation (TW-RUS) ad- 
vanced 0.9 year faster than expected uring the same 
period in untreated Turner patients [7]. The references 
for bone age (TW-RUS) [7] are based on girls with TS 
not treated with growth promoting substances, uch as 
GH or oestrogens. The accelerated skeletal maturation 
in the six patients treated with GH alone strongly indi- 
cates that GH alone is able to accelerate skeletal matura- 
tion. 
Before final height is actually reached, the effect of 
GH treatment on adult height can only be predicted. 
There are several methods for predicting adult height. 
Zachmann et al. [17] demonstrated that the GP method 
provided the most accurate height prediction in TS. How- 
ever, only six children were investigated. The reliability 
of the "projected height" based on extrapolation of the 
height centiles was investigated by Lyon et al. [5], who 
found a slight underprediction averaging -0 .6cm.  The 
results of the two prediction methods in our study before 
start of treatment were comparable: 144.1 (5.4) cm ac- 
cording to GP and 143.0 (4.7) by extrapolating height 
SDS. The prediction according to the method of GP in- 
creased by 5.6cm during 4 years of treatment. After 4 
years of treatment 11 of the 16 girls have exceeded their 
predicted adult height and also 11 of the 16 girls have ex- 
ceeded their projected height. Furthermore there was an 
increase in mean height SDS for bone age. These data 
suggest that final height might be increased as a result of 
treatment with GH. 
During this period four patients stopped GH treat- 
ment. The final heights exceeded the predicted heights 
by 0 to 3.4 cm and the projected heights by -2 .2  to 4 cm. 
These results are disappointing and are in contrast to the 
predicted increment of approximately 5 cm after 4 years 
of treatment in the whole group, although eight at dis- 
continuation of GH treatment is probably still somewhat 
lower than the future adult height. It is remarkable that 
one of the four patients topped growing at a bone age at 
which growth should still be possible [7]. Another girl 
grew poorly on GH alone, although bone age was only 
12.3 years. She responded very well after oxandrolone 
was added to the GH treatment. This illustrates that the 
growth promoting effect of oxandrolone is different in a 
qualitative sense from the effect of GH and it is well in 
line with the observation that GH and oxandrolone are 
additive in their effect [11]. It also indicates that on GH 
therapy growth may stop although the epiphyses in the 
hands have not yet fused, while further growth is possi- 
ble with an anabolic steroid. Further research into this 
phenomenon is necessary because of the important clini- 
cal consequences. 
In conclusion, in girls with TS GH increases height 
velocity but also accelerates skeletal maturation. The 
various prediction methods used for the 13 children who 
completed the treatment period of 4 years indicate that 
ultimate height will be approximately 5 cm higher than 
initially predicted adult height. However, there is con- 
siderable interindividual variation in the growth response 
to GH and the results in the four children who stopped 
GH treatment are disappointing. Therefore we feel that 
no firm conclusions can yet be drawn concerning the effi- 
cacy of GH therapy in terms of final height. 
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